| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

23-25 March 2026

BIO-Europe Spring 2026

Feira Internacional de Lisboa (FIL)

Lisboa

Portugal

17 March 2026

SmallCap Event 20th Edition

Les Salons Hoche

Paris

France

24-27 February 2026

Bio-Neuroscience 2026

Hotel Jakarta

Amsterdam

Netherlands

19 February 2026

ORYZON to participate in upcoming events in February and March

12 February 2026

ORYZON announces appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS

9 February 2026

ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in extensive stage small cell lung cancer

2 February 2026

ORYZON strengthens patent portfolio for vafidemstat with new Decision to Grant in Japan

29 January 2026

Allinvest Securities Biomed Forum

Le Salons Hoche

Paris

France

12-15 January 2026

44th Annual J.P. Morgan Healthcare Conference

San Francisco

CA

United States

11 January 2026

9th Sachs Annual Neuroscience Innovation Forum

Marines’ Memorial Club, San Francisco

CA

United States

Pagination

First page «
Previous page ‹
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel